THE MCMANUS GROUP for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2020 | $80,000 | Replaced |
| 2nd Quarter - Amendment | Jan 11, 2022 | $80,000 | Replaced |
| 2nd Quarter - Amendment | Aug 29, 2022 | $80,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Reforms related to the pharmaceutical supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL BRYAN CRONAN | — |
| JOHN MCMANUS | — |
| WILLIAM RHYNE | — |
| ALANNA TEMME | — |
Medicare/Medicaid MMM
Access and reimbursement in Parts B & D. Part D redesign. Lobbied against the International Pricing Index model (83 FR 54546).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | LD, Rep. Jon Porter |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.